EGFR c.2333T>C ;(p.L778P)

Variant ID: 7-55249035-T-C

NM_005228.3(EGFR):c.2333T>C;(p.L778P)

This variant was identified in 2 publications

View GRCh38 version.




Publications:


Hacking Pancreatic Cancer: Present and Future of Personalized Medicine.

Pharmaceuticals (Basel, Switzerland)
Di Federico, Alessandro A; Tateo, Valentina V; Parisi, Claudia C; Formica, Francesca F; Carloni, Riccardo R; Frega, Giorgio G; Rizzo, Alessandro A; Ricci, Dalia D; Di Marco, Mariacristina M; Palloni, Andrea A; Brandi, Giovanni G
Publication Date: 2021-07-15

Variant appearance in text: EGFR: L778P
PubMed Link: 34358103
Variant Present in the following documents:
  • Main text
  • pharmaceuticals-14-00677.pdf
View BVdb publication page



Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial.

Oncotarget
Wang, Jack P JP; Wu, Chen-Yi CY; Yeh, Yi-Cheng YC; Shyr, Yi-Ming YM; Wu, Ying-Ying YY; Kuo, Chen-Yu CY; Hung, Yi-Ping YP; Chen, Ming-Huang MH; Lee, Wei-Ping WP; Luo, Jiing-Chyuan JC; Chao, Yee Y; Li, Chung-Pin CP
Publication Date: 2015-07-20

Variant appearance in text: EGFR: L778P
PubMed Link: 26046796
Variant Present in the following documents:
  • Main text
  • oncotarget-06-18162.pdf
  • oncotarget-06-18162-s001.pdf
View BVdb publication page